Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05673018 · ClinicalTrials.gov registry record · NA

Galleri® in the Medicare Population.

A NA study of Cancer, sponsored by GRAIL.

Recruiting
Registry status
NA
Development phase
50,000
Enrollment target
20
Study locations

NCT05673018 is a NA study of Cancer that is actively recruiting participants, run by GRAIL. The registered enrollment target is 50,000 participants, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05673018, a NA study of Cancer, is actively recruiting participants, sponsored by GRAIL.

RECRUITING
Registry status
NA
Development phase
50,000 participants
Enrollment target
20
Study locations

Study Summary

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.

Conditions Studied

Interventions

  • DEVICE Multi-Cancer Early Detection Test (Galleri®)

Study Locations (20)

California

  • Sutter Valley Hospitals Auburn - Auburn
  • Sutter Valley Hospitals Davis - Davis
  • Sutter Valley Hospitals Elk Grove - Elk Grove
  • Long Beach Memorial Orange Coast - Fountain Valley
  • Long Beach Memorial Saddleback - Laguna Hills
  • Long Beach Memorial Atlantic - Long Beach
  • Sutter Valley Hospitals Modesto - Modesto
  • Sutter Valley Hospitals PAMF Sutter - Palo Alto
  • Sutter Valley Hospitals Roseville - Roseville
  • Sutter Valley Hospitals Alhambra - Sacramento
  • Sutter Valley Hospitals Capitol Pavilion - Sacramento
  • University of California San Francisco Health System - San Francisco
  • Sutter Valley Hospitals Santa Barbara - Santa Barbara
  • Sutter Valley Hospitals PAMF Santa Cruz - Santa Cruz
  • Sutter Health Santa Rosa - Santa Rosa
  • Sutter Valley Hospitals PAMF Sunnyvale - Sunnyvale
  • Sutter Valley Hospitals Fairfield - Vallejo

Georgia

  • Morehouse School of Medicine Atlanta - Atlanta
  • Morehouse School of Medicine Lee Street - Atlanta
  • Morehouse School of Medicine Princeton Lakes - Atlanta

Trial Details

FieldValue
Enrollment Target 50,000 participants
Start Date 2024-07-12
Est. Completion 2030-09
Phase NA

Sponsor

GRAIL

5 total trials

What the Registry Record Tells You About NCT05673018

The ClinicalTrials.gov registry entry for NCT05673018 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,410-participant average among 615 other Cancer trials with a reported enrollment target (1366% higher). The listed sponsor is GRAIL, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Multi-Cancer Early Detection Test (Galleri®) is the first listed.

NCT05673018 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05673018 about?

NCT05673018 is a clinical study titled "Galleri® in the Medicare Population.". This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.

What is the current status of trial NCT05673018?

This trial is currently recruiting. It is a NA study. The enrollment target is 50,000 participants. The study started on 2024-07-12. Estimated completion is 2030-09.

What conditions does trial NCT05673018 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT05673018?

The interventions under investigation include: Multi-Cancer Early Detection Test (Galleri®) (DEVICE).

Who is sponsoring clinical trial NCT05673018?

This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05673018 being conducted?

This trial has 20 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.